Approximately 8% to 12% of melanoma cases occur in a familial context.
1 The main high-penetrance gene implicated in melanoma susceptibility is
CDKN2A (OMIM code: 600160; GenBank accession number: NM_000077.4 [p16INK4A] and NM_058195.3 [p14ARF]). The gene encodes 2 tumor suppressor proteins: p16INK4A, which promotes cell-cycle arrest and plays a role in senescence, and p14ARF, which acts through p53-regulating apoptosis.
2,3 Germline
CDKN2A mutations are found in 20% to 40% of melanoma-prone families
4 and in 8% to 16% of patients with multiple primary melanomas without other cases in the family.
5 Patients with melanoma carrying
CDKN2A mutations have a younger age of onset and a higher number of primary melanomas, and the presence of
CDKN2A mutations is associated with dysplastic nevi.
4-7